#1 Clinical Trials Search in Europe

OMTX705

OMTX705 is an innovative antibody-drug conjugate currently being investigated in clinical trials for patients with advanced solid tumors. This open-label, multicenter Phase 1 study examines OMTX705 both as a standalone treatment and in combination with pembrolizumab (Keytruda) for patients who have exhausted standard treatment options. The trial aims to establish safe dosing levels, evaluate side effects, and gather preliminary data on the drug’s effectiveness against various advanced cancers. This article summarizes key information about this ongoing research to help patients understand this potential new treatment approach.

Table of Contents

What is OMTX705?

OMTX705 is an investigational medication currently being studied for the treatment of advanced solid tumors. It belongs to a class of drugs known as antibody-drug conjugates (ADCs), which are specialized treatments that combine a targeted antibody with a cancer-killing drug. Specifically, OMTX705 is an anti-fibroblast activation protein antibody-drug conjugate, meaning it targets a specific protein found in the environment surrounding tumors[1].

Currently, OMTX705 is being investigated in clinical trials and is not yet approved for general use. The research is exploring its potential both as a single treatment (monotherapy) and in combination with another cancer drug called pembrolizumab (brand name Keytruda)[1].

How OMTX705 Works

OMTX705 works by targeting fibroblast activation protein (FAP), which is found in cancer-associated fibroblasts (CAFs). These are special cells that exist in the environment surrounding tumors and can help cancer grow and spread[1].

The medication has two main parts:

  1. An antibody that specifically recognizes and attaches to the fibroblast activation protein
  2. A drug payload (called TAM470) that can kill cancer cells

By targeting these special cells in the tumor environment rather than just the cancer cells themselves, OMTX705 represents a different approach to cancer treatment[1].

Current Research on OMTX705

OMTX705 is currently being studied in a Phase 1 clinical trial (identified as NCT05547321). This study is designed to evaluate the safety and effectiveness of OMTX705 in patients with advanced or metastatic cancer who have no available standard treatment options[1].

The study has two main parts:

  • Part 1: A dose-escalation phase with two parallel groups – one receiving OMTX705 alone and another receiving OMTX705 combined with pembrolizumab. This phase helps researchers find the right dose by starting with a low dose (1.0 mg/kg) and gradually increasing it while monitoring for side effects[1].
  • Part 2: An expansion phase with up to 4 groups of patients (up to 15 patients each) to further confirm the safety of the selected dose and gather initial information about how effective the treatment might be against tumors[1].

Treatment Approaches with OMTX705

In the clinical trial, OMTX705 is being tested in two different approaches:

  • Monotherapy: OMTX705 is given by itself to see how effective it is on its own[1].
  • Combination therapy: OMTX705 is given together with pembrolizumab (Keytruda). Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. Researchers believe the combination might work better than either drug alone[1].

In the study, OMTX705 is administered on Days 1 and 8 in cycles of 21 days (meaning a 3-week cycle where you receive the drug twice)[1].

Safety Monitoring and Evaluations

The main goal of the current study is to evaluate the safety of OMTX705. Researchers are carefully tracking any treatment-emergent adverse events (TEAEs) – side effects that appear during the course of treatment[1].

Throughout the study, researchers are monitoring:

  • Safety: Tracking all side effects and their severity[1]
  • Pharmacokinetics: How the drug moves through the body, including how quickly it’s absorbed, distributed, and eliminated[1]
  • Immunogenicity: Whether the body develops antibodies against the drug (anti-drug antibodies or ADAs)[1]
  • QTc prolongation: Monitoring heart activity through electrocardiography (ECG) to ensure the drug doesn’t affect heart rhythm[1]
  • Biomarkers: Measuring changes in various markers in the blood that might indicate how the drug is working[1]

Potential Benefits of OMTX705

While it’s too early to know for certain how effective OMTX705 will be, the study is designed to look for signs of anti-tumor activity. Researchers are measuring the objective response rate (ORR), which includes:

  • Complete response (CR): When all detectable cancer disappears
  • Partial response (PR): When tumors shrink by a significant amount

These responses are measured using a standardized approach called RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), which helps doctors consistently measure changes in tumor size[1].

Who Might Benefit from OMTX705

The current study is focusing on patients with advanced solid tumors who have no available standard treatment options. This means the cancer is either:

  • Advanced: Cancer that has grown significantly within the organ it started in
  • Metastatic: Cancer that has spread from its original location to other parts of the body

If the clinical trials show promising results, future studies might focus on specific types of solid tumors where OMTX705 shows the most benefit. The current study allows for “enrichment” of expansion groups with particular types of cancer where activity has been observed during the dose-finding phase[1].

It’s important to note that OMTX705 is still in the early phases of clinical testing, and more research is needed before we know its full potential benefits and limitations for cancer treatment[1].

Feature Details
Trial Design Open-label, two-parallel arm, multicenter, Phase 1 dose-escalation study
Study Population Patients with advanced or metastatic solid tumors with no available standard therapeutic options
Treatment Arms 1. OMTX705 monotherapy
2. OMTX705 + pembrolizumab (Keytruda) combination
Dosing Schedule OMTX705 administered on Days 1 and 8 in 21-day cycles, starting at 1.0 mg/kg
Study Structure Part 1: Dose escalation to determine maximum tolerated dose
Part 2: Up to 4 expansion cohorts (up to 15 patients each) to confirm safety and assess tumor activity
Primary Outcome Safety evaluation through frequency and grade of treatment-emergent adverse events
Secondary Outcomes – Preliminary signs of antitumor activity
– OMTX705 pharmacokinetics
– OMTX705 immunogenicity
Other Assessments – Cancer serum biomarkers
– OMTX705 biomarkers
– Payload metabolites
– QTc prolongation
– Cancer-associated fibroblasts
Follow-up – End of Treatment visit 30 days after last dose
– Progression-free survival follow-up every 12 weeks
– Survival follow-up every 3 months (Part 2 only)
Expected Timeline Average of 24 months

FAQ

  • What is OMTX705 and how does it work? OMTX705 is an antibody-drug conjugate (ADC) that targets fibroblast activation protein (FAP). It works by delivering a cancer-fighting payload (TAM470) directly to cancer-associated fibroblasts in the tumor microenvironment. This targeted approach aims to destroy cancer cells while minimizing damage to healthy tissues.
  • Who is eligible to participate in the OMTX705 clinical trial? The trial is designed for patients with advanced or metastatic solid tumors who have no available standard therapeutic options left. Participants are assigned to either receive OMTX705 alone or in combination with pembrolizumab, an immunotherapy drug.
  • How is the OMTX705 treatment administered? OMTX705 is administered intravenously on Days 1 and 8 in 21-day treatment cycles. When used in combination therapy, it's given with pembrolizumab. The starting dose in the trial is 1.0 mg/kg, with the possibility of dose adjustments based on safety findings.
  • What is the purpose of combining OMTX705 with pembrolizumab? The combination approach tests whether OMTX705 works better when paired with pembrolizumab (Keytruda), which is an established immunotherapy that helps the immune system detect and fight cancer cells. The trial will compare the safety and effectiveness of OMTX705 alone versus the combination to determine the optimal treatment approach.
  • What types of assessments are performed during the OMTX705 trial? Participants undergo several assessments including: monitoring for side effects, tumor imaging to evaluate response to treatment, blood tests to measure drug levels and biomarkers, tests for anti-drug antibodies, electrocardiograms to check for heart rhythm changes, and analysis of cancer-associated fibroblasts. These assessments help researchers understand how the drug works and whether it's effectively fighting cancer.

Ongoing Clinical Trials on OMTX705

  • Study on the Safety and Effectiveness of OMTX705 with Regorafenib and Tislelizumab for Patients with Advanced Colorectal Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Testing OMTX705 Combined with Carboplatin, Pemetrexed, and Tislelizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Spain

Glossary

  • Antibody-drug conjugate (ADC): A type of targeted therapy that combines an antibody (which targets specific proteins on cancer cells) with a cancer-killing drug. OMTX705 is an ADC that targets fibroblast activation protein.
  • Advanced solid tumor: Cancer that has spread from where it started to surrounding tissues or other parts of the body. Solid tumors form a mass of tissue and don't contain cysts or liquid areas.
  • Fibroblast activation protein (FAP): A protein found on cancer-associated fibroblasts in the tumor microenvironment. OMTX705 targets this protein.
  • Cancer-associated fibroblasts (CAFs): Specialized cells in the area surrounding a tumor that can promote cancer growth and spread. These cells are targeted by OMTX705.
  • Dose-escalation trial: A type of clinical trial where the dose of the drug is gradually increased to find the optimal balance between effectiveness and safety.
  • Maximum tolerated dose (MTD): The highest dose of a drug that doesn't cause unacceptable side effects. This is one of the primary goals of the OMTX705 Phase 1 trial.
  • Monotherapy: Treatment with a single drug, in this case using OMTX705 alone.
  • Combination therapy: Treatment using more than one drug, in this case OMTX705 plus pembrolizumab.
  • Pembrolizumab (Keytruda): An immunotherapy drug that helps the immune system detect and fight cancer cells. It's being tested in combination with OMTX705 in this trial.
  • Phase 1 trial: The first stage of clinical testing in humans, primarily focused on determining safety, side effects, and appropriate dosing of a new treatment.
  • Open-label study: A type of clinical trial where both researchers and participants know which treatment is being administered.
  • Recommended Phase 2 dose (RP2D): The dose determined to be appropriate for further testing in larger Phase 2 trials based on safety findings from Phase 1.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. It includes complete responses and partial responses.
  • Complete response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial response (PR): A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors – a standardized set of rules used to assess how tumors respond to treatment in cancer clinical trials.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Biomarker: A measurable substance in the body that may indicate disease, infection, or environmental exposure. In cancer trials, biomarkers can help track response to treatment.
  • Anti-drug antibodies (ADAs): Proteins produced by the immune system that recognize and bind to therapeutic drugs, potentially reducing their effectiveness or causing side effects.
  • Treatment-emergent adverse events (TEAEs): Side effects or other undesirable events that occur after treatment has started and were not present before treatment began.
  • QTc prolongation: A heart rhythm condition that can potentially cause fast, chaotic heartbeats. The OMTX705 trial monitors for this using electrocardiograms.

References

  1. https://clinicaltrials.gov/study/NCT05547321